Rankings / Longevity — Senolytics & Polyphenols
RLS-1496 (Rubedo)
Longevity · Senolytic (GPX4 modulator)
Tier D
Bottom line
Read Off Label grades RLS-1496 (Rubedo) as D (3.3/10) based on weak evidence, low benefit magnitude, and a unclear-risk safety profile.
The senolytic idea finally reaching human skin with a randomized, vehicle-controlled design.
Studied, labeled, or reported-use context: Topical cream; the EU Phase 1 used ascending doses, the US Phase 1b/2a uses 1. — Investigational; not individualized guidance.
What the evidence says
The senolytic idea finally reaching human skin with a randomized, vehicle-controlled design. Rubedo reported preliminary Phase 1 results in March 2026 from a single-centre, ascending-dose, randomized, double-blind, vehicle-controlled EU trial across three populations — plaque psoriasis, atopic dermatitis, and photo-aged skin — treating for one month. It met its primary safety and tolerability endpoint and showed a clinical signal in four weeks: senescent-cell reduction and roughly 20% less epidermal thickness in the mid- and high-dose psoriasis cohorts, a >=4-point itch improvement in 25% of atopic-dermatitis subjects against none on vehicle, and in photo-aged skin dose-dependent target engagement with collagen gene and protein expression rising and senescence-associated secretory phenotype markers falling on spatial transcriptomics. What to hold onto: every number here comes from a company press release, not a peer-reviewed paper, so the evidence rating stays Weak regardless of how good the design sounds. The mechanism is also a genuinely different bet from the senolytics readers already know — this is GPX4 and ferroptosis, not the BCL-2/BCL-xL family that dasatinib + quercetin, fisetin and foselutoclax work through, so the platelet toxicity that constrains BCL-xL drugs does not apply and the topical route reflects the skin indications rather than a systemic safety ceiling. A US Phase 1b/2a in actinic keratosis (NCT07340697, n=24, treated forearm versus untreated forearm) is listed to complete in 2026. Nothing here is evidence about lifespan, healthspan, or any tissue other than skin.
Mechanism
Topical small-molecule GPX4 modulator. GPX4 is the enzyme that shields cells from ferroptosis, an iron-dependent form of cell death; senescent cells depend on it unusually heavily to stay alive, so modulating it is intended to tip them into ferroptosis while leaving normal cells alone. The first GPX4 modulator taken into human trials
Studied, labeled, or reported dose & route
Topical cream; the EU Phase 1 used ascending doses, the US Phase 1b/2a uses 1.0% once daily for 28 days
This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.
Citations
A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.
Common questions
- What does the evidence show about RLS-1496 (Rubedo)'s effects?
- Read Off Label rates the evidence for RLS-1496 (Rubedo) as Weak and the benefit magnitude as low, producing an overall grade of D (3.3/10). The senolytic idea finally reaching human skin with a randomized, vehicle-controlled design.
- What safety findings are reported for RLS-1496 (Rubedo)?
- RLS-1496 (Rubedo) has a unclear risk profile in the database. Unknown (topical; the Phase 1 met its safety and tolerability endpoint but no adverse-event detail has been published; systemic absorption, long-term use, and any consequence of blunting a ferroptosis defence in healthy tissue are all untested) Legal status: Investigational (EU Phase 1 complete; US Phase 1b/2a in actinic keratosis ongoing — NCT07340697, completion listed 2026).
- What doses or routes are reported for RLS-1496 (Rubedo)?
- Topical cream; the EU Phase 1 used ascending doses, the US Phase 1b/2a uses 1.0% once daily for 28 days This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
- How does RLS-1496 (Rubedo) work?
- Topical small-molecule GPX4 modulator. GPX4 is the enzyme that shields cells from ferroptosis, an iron-dependent form of cell death; senescent cells depend on it unusually heavily to stay alive, so modulating it is intended to tip them into ferroptosis while leaving normal cells alone. The first GPX4 modulator taken into human trials
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.